Rhythm Pharmaceuticals Inc. (referred to as Rhythm Pharmaceuticals) recently disclosed that some of its shareholders plan to further sell up to 2.4 million shares of common stock.

This stock sale plan is led by existing shareholders, aiming to achieve their personal asset allocation goals. The transaction is expected to provide additional liquidity to the market, while potentially having some impact on the existing equity structure. The company emphasizes that this stock sale is a personal financial arrangement by the shareholders and does not involve the issuance of new shares by Rhythm Pharmaceuticals, so it will not have a dilutive effect on the company's total capital.